BPC-157 + KPV - REGEN-type

1 Identity

Fixed-ratio two-component article: a 15-residue synthetic peptide co-lyophilized with a synthetic tripeptide. A formulation, not a substance. and "BPC/KPV" — market names. It is the simplest blend in this group and the two-component subset of the Coremend and KLOW compositions, which are separate records in the catalog.

Contains BPC-157 + KPV

Sequence

Per component, cross-referenced. BPC-157: GEPPPGKPADDAGLV, 15 residues, all L, free N-terminal amine, free C-terminal acid, no cysteine. KPV: H-Lys-Pro-Val-OH, three residues, all L, free acid specified; the C-terminal amide H-Lys-Pro-Val-NH2 is a different molecule 0.98 Da lighter and is treated as a specified impurity rather than a synonym.

Molecular formula

Per component. BPC-157 C62H98N16O22 (free acid, free base). KPV C16H30N4O4 (free acid); the amide is C16H31N5O3, and the salt forms are mono-acetate C18H34N4O6, mono-TFA C18H31F3N4O6 and bis-TFA C20H32F6N4O8, the last being 40.0 percent counterion by gross weight. No combined formula is written; a mixture has none. The total nominal fill is stated alongside the per-component fills.

Average mass

Per component: BPC-157 1,419.556 Da; KPV 342.440 Da, or 402.49 as the mono-acetate, 456.46 as the mono-TFA and 570.49 as the bis-TFA. At an observed 10 + 10 mg presentation, total nominal fill 20 mg: 7.044 micromol BPC-157 against 29.202 micromol KPV, a 1.00 : 4.15 molar ratio from a 1 : 1 mass ratio. On a two-component article with a four-fold mass difference between the molecules, the mass ratio and the molar ratio diverge by more than the ratio acceptance criterion itself, and the certificate states which of the two it is reporting.

Monoisotopic mass

Per component: BPC-157 1,418.7042 Da neutral, [M+H]+ 1,419.7115, [M+2H]2+ 710.3594. KPV 342.22671 Da neutral, [M+H]+ 343.23399, [M-H]- 341.21943, with the C-terminal amide at 341.24269 neutral. At 0.98 Da separation on a 342 Da molecule a nominal-mass instrument cannot discharge the free acid versus amide question, and its output is not accepted for this component.

Salt / variant note

(1) the KPV fork, which is the live risk on this article: free acid 342.44 against C-terminal amide 341.46, the two sold under the shared title "alpha-MSH(11-13)" by two different institutional houses with no "amide" in either product name; plus KdPT, Lys-D-Pro-Thr, 344.41, a different sequence carrying a D-proline. (2) BPC-157 salt forms: trifluoroacetate most often, sometimes acetate; the L-arginine salt is a separate record in the catalog. (3) ratio: no standard presentation exists and observed products differ. (4) the governing KPV degradant cyclo(Lys-Pro), 225.29, with co-released free valine, 117.15 — which belongs here because free valine released by degradation lands directly in the pool used to quantify KPV.

2 Class & testing panel

Form

Fixed-ratio blend

Testing panel

P1 — panel definitionfor both components, run per component. No metal, no lipid, no acylation, no D-residue and no non-proteinogenic residue in either component; neither carries an aromatic residue, so the article as a whole has NO 280 nm chromophore and a 280 nm purity trace on it is a method copied from somewhere else. Two composition-specific rules govern the calculation. First, aspartate serves as the per-component marker for BPC-157 here because KPV contains no aspartate, but it holds by coincidence of composition rather than as a general rule and fails in every blend of this family that also contains full-length thymosin beta-4, so the marker is derived per blend from the composition rather than carried between records. Second, because free valine is both the analyte used to recover KPV by difference and a degradation product of KPV itself, the free-valine result from the stability-indicating method is subtracted before the difference is taken; without that correction a degrading lot reports a rising KPV content, which is the wrong direction

3 Primary sources & evidence

The index reports the design and provenance of the literature, not a conclusion about effect.

Literature exists for each component and is graded and cited on that component's record. The KPV file is entirely preclinical and analytical, and the human clinical material circulating under the KPV name belongs to KdPT, which is a different molecule. None of it is literature about this mixture: no published study of this fixed two-component combination has been identified.

4 Storage & specification

Storage

Co-lyophilized solid at -20 degrees C plus or minus 5 degrees C, tightly closed and desiccated with in-pack desiccant, protected from light, the sealed vial equilibrated to room temperature before opening; the labeled condition is the more restrictive of the two components. Neither component contains methionine, cysteine or tryptophan, so oxidation is not the governing pathway on this article and a nitrogen blanket is good practice rather than a control. Moisture is the control, because diketopiperazine formation at the KPV Lys-Pro N-terminus is moisture- and temperature-accelerated. 2-8 degrees C is acceptable for transit and for working stock held no longer than 30 days.

Shelf life

Provisional at 24 months at -20 degrees C plus or minus 5 degrees C, taken as the shorter of the two component intervals and provisional pending this company's own data. A mandatory 6-month interim pull on each of the first three blend lots assays specifically for cyclo(Lys-Pro) and free valine rather than for total impurities, because a rising free-valine result degrades the KPV content determination itself and not only the purity figure. Also trended are per-component content, the measured ratio, water content and any new peak above 0.10 percent.